Focal degeneration of basal cells and the resultant auto-immunoreactions: A novel mechanism for prostate tumor progression and invasion

Medical Hypotheses

Volumn 70, Issue 2, 2008, Pages 387-408

  Man, Yan Gao ^a   Gardner, William A ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P63; PROTEINASE; TENASCIN; TUMOR MARKER;

ARTICLE; AUTOIMMUNITY; BASAL CELL; BASEMENT MEMBRANE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER STEM CELL; CANCER THERAPY; CELL DEATH; CELL DEGENERATION; CELL FUNCTION; CELL INFILTRATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL EVALUATION; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; MAST CELL; PATIENT CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TISSUE WATER;

AUTOIMMUNITY; CELL PROLIFERATION; GENE EXPRESSION; HUMANS; LEUKOCYTES; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MAST CELLS; MEMBRANE PROTEINS; MODELS, IMMUNOLOGICAL; NEOPLASM INVASIVENESS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; STROMAL CELLS; TENASCIN;

EID: 37349003357     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.05.015     Document Type: Article

References (108)

1. Carruba G., Stefano R., and Cocciaeliferro L. Intercellular communication and human prostate carcinogenesis. Ann NY Acad Sci 963 (2002) 156-168
2. Goldstein N.S., Underhiel J., Roszka N., and Neill J.S. Cytokeratn 34 beta E-12 immunoreactivity in benign prostate acini. Quantization, pattern assessment, and electron microscopic study. Am J Clin Pathol 112 (1999) 69-74
3. Bonkhoff H., Wernert N., Dhom G., and Remberger K. Basement membranes in fetal, adult normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 418 (1991) 375-381
4. Kosir M.A., Wang W., Zukowski K.L., and Tromp G. Degradation of basement membrane by prostate tumor heparanase. J Surg Res 81 (1999) 42-47
5. Bonkhoff H., and Remberger K. Morphogenesis of benign prostatic hyperplasia and prostatic carcinoma. Pathologe 19 (1998) 12-20
6. Bostwick D.G. Prospective origins of prostate carcinoma. Prostate intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 78 (1996) 330-336
7. Haggman M.J., Macoska J.A., Wojno K.J., and Oesterling J.E. The relationship between prostate intraepithelial neoplasia and prostate cancer: critical issues. J Urol 58 (1997) 12-22
8. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 9361 (2003) 955-964
9. Ashida S., Nakagawa H., Katagiri T., Furihata M., Liizumi M., Anazawa Y., et al. Molecular features of the transition from prostate intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 64 (2004) 5863-5872
10. Webber M.M., Waghray A., and Bello D. Prostate-specific antigen, a serine protease, facilitates human cancer cell invasion. Clin Cancer Res 1 (1995) 1089-1094
11. Barsky S.H., Siegal G.P., Jannotta F., and Liotta L.A. Loss of basement membrane components by invasive tumors but not by the benign counterparts. Lab Invest 49 (1983) 140-147
12. Goldfarb R.H., and Liotta L.A. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemost 12 (1986) 294-307
13. Stearns M., and Stearns M.E. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 8 (1996) 69-75
14. Abramjuk C., Jung K., Krell H.W., Juchem P., Peters R., Taymoorian K., et al. Matrix metalloproteinase inhibitor RO 28-2653 in combination with estramustine: tumor-reduced effects on hormone-sensitive prostate cancer in rats. Anticancer Drug 16 (2005) 855-861
15. Kasahara Y., and Tsukada Y. New insights and future advances in cancer diagnostics: limitations of conventional tumor markers. In: Nakarnura R.M., Grody W.W., Wu J.T., and Nagle R.B. (Eds). Cancer diagnostics: current and future trends (2004), Humanna Press, Totowa (NJ) 15-26
16. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
17. Warnberg F., Nordgren H., Bergkvist L., and Hulmberg L. Tumor markers in breast carcinomas correlate with grade rather than with invasiveness. Br J Cancer 85 (2001) 869-874
18. Bostwick D.G. Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 30 (1996) 145-152
19. Mostofi F.K., Sesterhenn I.A., and Davis Jr. C.J. Prostatic intraepithelial neoplasia (PIN): morphological clinical significance. Prostate Suppl 4 (1992) 71-77
20. Harvei S., Skijorten F.J., Robsahm T.E., Berner A., and Tretli S. Is prostaticibtraepithelial neoplasi in the transitio/central zone a true presursor of cancer? A long-tern retrospectivestudy in Norway. Br J Cancer 78 (1998) 46-49
21. Goeman L., Joniau S., Ponette D., Van der Aa F., Roskams T., Oyen R., et al. Is low-grade prostatic intraepithelial neoplasia a risk factor for cancer. Prostate Cancer Prostatic Dis 6 (2003) 305-310
22. Bonkhoff H., and Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28 (1996) 98-106
23. Joniau S., Goeman L., Pennings J., and Van Poppel H. Prostatic intraepithelial neoplasia (PIN): importance and clinical management. Eur Urol 48 (2005) 379-385
24. Bostwick D.G. Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Urol Oncol 17 (1999) 187-209
25. Haggman M.J., Adolfsson J., Khoury S., Montie J.E., and Norlen J. Clinical management of premalignant lesions of the prostate. WHO Collaborative Project and Consensus Conference on Public Health and Clinical signance of Premalignant Alterations in the Genitourinary Tract. Scand J Urol Nephol Suppl 205 (2000) 44-49
26. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science 295 5564 (2002) 2387-2392
27. Matrisian L.M., Sledge Jr. G.W., and Mohla S. Exacellular proteolysis and cancer: meeting summary and future directions. Cancer Res 63 (2003) 6105-6109
28. Parker S.L., Tong T., Bolders S., and Wingo P.A. Cancer statistics. Cancer J Clin 47 (1997) 5-27
29. Bostwick D.G., Qian J., and Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol 154 (1885) 1791-1794
30. Dovey Z., Corbishley C.M., and Kirby R.S. Prostatic intraepithelial neoplasia: a risk factor for prostate cancer. Can J Urol Suppl 1 (2005) 49-52
31. Ruoppolo M. Early diagnosis of prostatic cancer: disease-related survival improvement or extension of observation time?. Arch Ital Urol Androl 77 (2005) 169-172
32. Signoretti S., Waltregny D., Dilks J., et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157 (2000) 1769-1775
33. Kurita T., Medina R.T., Mills A.A., and Cunha G.R. Role of p63 and basal cells in prostate. Development 131 (2004) 4955-4964
34. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263 (1994) 526-529
35. Bostwick D.G., and Brawer M.K. Prostate intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 59 (1987) 788-794
36. Smith C.J., and Gardner Jr. W.A. Inflammation-proliferation: possible relationship in the prostate. Prog Clin Biol Re 239 (1987) 317-325
37. Man Y.-G., Shen T., Zhao Y.G., and Sang Q.X.A. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: A potential mechanism for basal cell layer degradations and tumor invasion. Cancer Detect Prev 29 (2005) 161-169
38. Man YG, Sang QXA, Zhao CQ, Mannion C, Gardner WA. Focal basal cell degeneration with T-lymphocyte and mast cell infiltration triggers onset of prostate tumor invasion. Cancer Detect Prev [in press].
39. Bonkhoff H., Stein U., and Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 24 (1994) 114-118
40. Bounkhoff H. Role of the basal cells in premalignant changes of the human prostate: a stem cell concept for the development of prostate cancer. Eur Urol 30 (1996) 201-205
41. Botticelli A.R. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate. Pathologica 86 (1994) 128-141
42. Man Y.-G., Shen T., Zhao Y.G., and Sang Q.X. Morphologically comparable prostate acini and ducts with and without a focal basal cell layer disruption have a different cell proliferation rate: Implications for tumor invasion. FASEB 18 5 (2004) A1193
43. Man Y.-G., Shen T., Zhao Y.G., and Sang Q.X. Focal prostate basal cell layer disruptions and leukocyte infiltration are correlated events: implications for basal call layer degradation and tumor invasion. Cancer Detect Prev S-51 (2004) 15 [2004 Symposium Issue]
44. Man Y.-G., Mannion C., and Shen T. Localized basal cell degeneration and resultant immunoreactions are a triggering factor for prostate tumor invasion. FASEB 19 (2005) A1517-A1518 860.10
45. Zhao C., Mannion C., and Man Y.-G. Potential roles of cytotoxic T-lymphocytes and natural killer cells in prostate basal cell layer disruptions and tumor invasion. Mod Pathol 18 (2005) 175A 809
46. Zhao C.Q., and Man Y.-G. A subset of morphologically distinct prostate basal cells lacks expression of corresponding phenotypic markers (abstract). Am J Clin Pathol 124 4 (2005) 658-659
47. Sang Q.X.A., Zhao Y.G., and Man Y.-G. Mechanism of human prostate cancer invasion: basement membrane degradation and basal cell layer disruption. Proc Am Assoc Cancer Res 46 (2005) 1106 4689
48. Man Y.-G., Chen X.L., Garcia F.U., and Gardner W.A. Reduced p63 expression and elevated apoptosis in focally disrupted prostate basal cell layers: implications for tumor invasion. Lab Invest 86 (2006) 292A 1358
49. Man Y.-G., Egland K.A., Onda M., Nagata S., and Pastan I. Expression of BPSR correlates with breast and prostate tumor progression and invasion. Proc Am Assoc Cancer Res 47 (2006) 2896
50. Man YG, Liu XF, Mason J, Prabhakar S, Wang B, Zeng X. Prostate tumor cells near and distant from focally disrupted basal cell layers have different gene expression profiles. In: American Society Cell Biology 46 Annual Meeting, vol. 143; 2006. p. 1843.
51. Man Y.-G., Zhao C.Q., Wang J., and Chen X.L. A subset of prostate basal cells lacks corresponding phenotypic markers. Pathol Res Pract 202 9 (2006) 651-662
52. Verstraeten A.A., Mackie E.J., Hageman P.C., et al. Tenascin expression in basal cell carcinoma. Brit J Dermt 127 (1992) 571-574
53. Ilunga K., Nishiura R., Inada H., El-karef A., Imanaka-Yoshida K., Sakakura T., et al. Co-stimulation of human breast cancer cells with transforming growth factor-beta and tenasicin-c enhances matrix metalloproteinase-9 expression and cancer cell invasion. Int J Exp Pathol 85 (2004) 373-379
54. Zhang R., Man Y.-G., Vang R.S., Saenger J.S., Barner R., Wheeler D., et al. A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res 5 (2003) R151-R156
55. Man Y.-G., Tai L., Barner R., Vang R., Saenger J.S., Shekitka K.M., et al. Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion. Breast Cancer Res 5 (2003) R231-R241
56. Man Y.-G., and Sang Q.X.A. The significance of focal myoepithelial cell layer disruptions in breast tumor invasion: a paradigm shift from the "protease-centered" hypothesis. Exp Cell Res 301 (2004) 103-118
57. Yousefi M., Mattu R., Gao C., and Man Y.-G. Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: implications for tumor progression and invasion. Appl Immunohistochem Mol Morph 13 (2005) 30-37
58. Man Y.-G., Zhang Y., Shen T., et al. cDNA expression profiling identifies elevated expressions of tumor progression and invasion related genes in cell clusters of in situ breast tumors. Breast Cancer Res Treat 89 (2005) 199-208
59. Man Y.-G., Shen T., Weisz J., Berg P.E., Schwartz A.M., Mulshine J.L., et al. A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion. Cancer Detect Prev 29 (2005) 221-231
60. Man Y.-G., and Nieburgs H.E. A subset of cell clusters with malignant features in morphologically normal and hyperplastic breast tissues. Cancer Detect Prev 30 3 (2006) 239-247
61. Man Y.-G., Zhao C.Q., and Wang J. Breast tumor cell clusters and their budding derivatives show different immunohistochemical profiles during stromal invasion: implications for hormonal and drug therapies. Cancer Therapy 4 (2006) 193-204
62. Man Y.-G., Vinh T., Zhao C., Walker A., and Barner R. Potential roles of T-lymphocytes and natural killer cells in human myoepithelial cell layer disruptions and tumor invasion. Mod Pathol 18 (2005) 42A 179
63. Man YG. A subset of cell clusters overlying focal myoepithelial cell layer disuptions exhibits features of mutated stem cells. In: Proceedings of Department of Defense Breast Cancer Research Program meeting P38-12; 2005. p. 263.
64. Man YG. CD8 and mast cell tryptase positive cells are preferentially associated with focal myoepithelial cell layer disruptions: implications for breast tumor invasion. In: Proceedings of Department of Defense Breast Cancer Research Program meeting P38-13; 2005. p. 263.
65. Man Y-G Berg PE, Sang QXA. Differential expression of tumor invasion related proteins in cells overlying focally disrupted myoepithelial cell layers and adjacent cells within the same duct. In: Proceedings of Department of Defense Breast Cancer Research Program meeting P10-5; 2005. p. 75.
66. Man Y-G. Focal degenerations in surrounding structures and infiltration of immunoreactive cells are a potential trigger for invasion of breast and other epithelium-derived tumors. In: Proceedings of Department of Defense Breast Cancer Research Program meeting P10-7; 2005. p. 75-6.
67. Wang H.L., and Man Y.-G. Potential roles of focal basement membrane disruptions and lymphocyte infiltration in colorectal cancer invasion. Am J Clin Pathol 124 4 (2005) 647
68. Nelson A., and Man Y.-G. Mast cells in high grade lesions of patients co-infected with human papilloma virus and human immunodeficiency virus. Lab Invest 86 (2006) 257A; 1190
69. Brummer T., Schramek D., Hayes V.M., Bennett H.L., Callon C.E., Musgrove E.A., et al. Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 281 (2006) 626-631
70. Oliveira A.M., Ross J.S., and Fletcher J.A. Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol 124 Suppl. (2005) S16-S28
71. Yanochko G.M., and Eckhart W. Type 1 insulin-like growth factor overexpression induce proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res 8 2 (2006) R18-R23
72. Boulikas T. Control of DNA replication by protein phosphorylation. Anticancer Res 14 (1994) 2465-2472
73. Boulikas T. Phosphorylation of transcription factors and control of the cell cycle. Crit Rev Eukaryot Gene Expr 5 (1995) 1-77
74. Chakravarthy M.V., Spangenhurg E.E., and Booth F.W. Culture in low levels of oxygen enhances in vitro proliferation potential of satellite cells from old skeletal muscles. Cell Mol Life Sci 58 (2001) 1150-1158
75. Csete M., Walikonis J., Slawny N., et al. Oxygen-mediated regulation of skeletal muscle satellite cell proliferation and adipogenesis in culture. J Cell Phys 189 (2001) 189-196
76. Studer L., Csete M., and Lee S.H. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowed oxygen. J Neurosci 20 (2000) 7377-7383
77. Asano-kato N., Fukagawa K., and Okada N. Tryptase increase proliferative activity of human conjunctive fibroblasts through protease-activated receptor. Invest Ophthalmol Vis Sci 46 (2005) 4622-4626
78. Freeman M.R., Schneck F.X., Gognon M.L., Corless C., Soker S., Niknejad K., et al. Peripheral blood T-lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55 (1995) 4140-4145
79. Nienartowicz A., Sobaniee-Lotowska M.E., et al. Mast cells in neoangiogenesis. Med Sci Monit 12 3 (2006) 53-56
80. Qu Z. Immunohistological detection of growth factors and cytokines in tissue mast cells. Meth Mol Biol 315 (2006) 257-272
81. Takahashi Y., Bucana C.D., Liu W., et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88 (1996) 1146-1151
82. Kang Y., and Massague J. Epithelial-mesenchymal transition: twist in development and metastasis. Cell 118 (2004) 277-279
83. Sato T., Sakai T., Noguchi Y., Takita M., Hirakawa S., and Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92 (2004) 47-56
84. Strizzi L., Bianco C., and Normanno N. Epithelial-mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Criptol-1 transgenic mice. J Cell Physiol 201 (2004) 266-276
85. Deng G., Liu Y., Ziotnikov G., et al. Loss of heterogosity in normal tissue adjacent to breast carcinomas. Science 274 5295 (1996) 2057-2059
86. Malins D.C., Polissar N.L., Su Y., Gardner H.S., and Gunselman S.J. A new structural analysis of DNA using statistical models of infrared spectra. Nat Med 3 (1997) 927-930
87. Malins D.C., Johnson P.M., Barker E.A., Polissar N.L., Wheeler T.M., and Anderson K.M. Cancer-related changes in prostate DNA as men age and early identification of metastasis in prostate tumors. Proc Natl Acad Sci USA 100 (2003) 5401-5406
88. Malins D.C., Anderson K.M., Gilman N.K., Green V.M., Barker E.A., and Hellstrom K.E. Development of a cancer DNA phenotype prior to tumor formation. Proc Natl Acad Sci Sci USA 101 (2004) 10721-10725
89. Malins D.C., Gilman N.K., Green V.M., Wheeler T.M., Barker E.A., and Anderson K.M. A DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA 102 (2005) 19093-19096
90. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 4260 (1976) 23-28
91. Sell S., and Pierce G.B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 70 (1994) 6-22
92. Kordon E.C., and Smith G.H. An entire functional mammary gland may comprise the progeny from a single cell. Development 125 (1998) 1921-1930
93. Middleton L.P., Vlastos G., Mirza N.Q., Eva S., and Sahin A.A. Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer 94 (2000) 1910-1916
94. Bjerkvig R., Tysnes B.B., Aboody K.S., et al. Opinion: the origin of the cancer stem cell: current controversies and new insight. Nat Rev Cancer 5 (2005) 899-904
95. Benoist C., and Mathis D. Mast cells in autoimmune disease. Nature 420 (2002) 875-878
96. Palapattu G.S., Sutcliffe S., Bastian P.J., Platz E.A., De Marzo A.M., Isaacs W.B., et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 26 (2005) 1170-1181
97. Steadman R., Irwin M.H., St John P.L., Blackburn W.D., Heck L.W., and Abrahamson D.R. Laminin cleavage by activated human neutrophils yields proteolytic fragments with selective migratory properties. J Leukoc Biol 53 (1993) 354-365
98. Heck L.W., Blackburn W.D., Irwin M.H., and Abrahamson D.R. Degradation of basement membrane laminin by human neutrophil elastases and cathepsin G. Am J Pathol 136 (1990) 1267-1274
99. Peek Jr. R.M., Mohla S., and DuBois R.N. Inflammation in the genesis and perpetuation of cancer:summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res 65 (2005) 8583-8586
100. MacLennan G.T., Eisenberg R., Fleshman R.L., et al. The influence of chronic inflammation in prostatic carcinogenesis: a 5-year follow-up study. J Urol 176 (2006) 1012-1016
101. Fibach E., Landau T., and Sachs L. Normal differentiation of myeloid leukaemic cells induced by a differentiation-inducing protein. Nat New Biol 237 (1972) 276-282
102. Nakamura T., Matsumoto K., Kiritoshi A., Tano Y., and Nakamura T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 57 (1997) 3305-3313
103. Silberstein G.B. Tumour-stromal interactions. Role of the stroma in mammary development. Breast Cancer Res 3 (2001) 218-223
104. Man Y.-G., Magrane G.G., Lininger R.A., Shen T., Kuhls E., and Bratthauer B.L. Morphologically similar epithelial and stromal cells in primary bilateral breast tumors display different genetic profiles: implications for treatment. Appl Immunohistochem Mol Morphol 12 (2004) 305-314
105. Moinfar F., Man Y.-G., Arnould L., Bratthauer G.L., Ratschek M., and Tavassol F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 60 (2000) 2562-2566
106. Man Y.-G., Martinez A., Avis I.M., Hong S.H., Cuttitta F., Venzon D.J., et al. Phenotypically different respiratory epithelial cells with hnRNP A2/B1 over-expression display similar genetic alterations. Am J Respir Cell Mol Biol 23 (2000) 636-645
107. Man Y.-G., Mannion C., Albores-Saaverdra J., et al. Allelic losses at 3p and 11p are detected in both epithelial and stromal components of cervical small cell neuroendocrine carcinoma. Appl Immunohistochem Mol Morphol 9 (2001) 340-345
108. Moinfar F., Gogg-Kamerer M., Sommersacher A., et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am J Surg Pathol 29 (2005) 485-489